Opinion on R&D in Germany

Select information type

Refine your search

search
Search tips

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Schering AG: harvesting the benefits

Schering AG's June sale of its Aventis CropScience stake has provided a E1.5 billion cashpile, which the company is investing in its pharma business. Two deals completed in the last week should boost the German firm's profile as an innovative biotech-focused pharma company, driving near-double-figure annual growth for the next five years.

Published By Datamonitor
03 Jul 2002
Expert View
Expert View

Multiple Sclerosis: the search for a vaccine continues

There are approximately 250,000 to 350,000 diagnosed cases of multiple sclerosis in the US, yet it is estimated that the actual number of Americans with MS may be even higher. As a new approach to the treatment of MS, vaccines have the potential to be both efficacious and cost effective. But can a vaccine be developed as a viable treatment for MS?

Published By Datamonitor
02 Aug 2002
CommentWire
CommentWire

MorphoSys/Roche: antibody hopes for Alzheimer's

German biotech MorphoSys and its partner Roche have achieved a key milestone in discovering a series of antibodies to treat CNS disorders such as Alzheimer's disease. While there are still serious technical and clinical challenges ahead, this innovative new development is certainly good news for Europe's biotechnology sector.

Published By Datamonitor
10 Jul 2002
CommentWire
CommentWire

Medigene: new treatments for genital warts

Published By Datamonitor
19 Oct 2001
CommentWire
CommentWire

KPN Mobile: the second coming isn't pre-paid

While i-mode is being hailed as the 'second coming' for European mobile data services, various obstacles may deter its uptake. In particular, KPN is not rolling out a pay-as-you-go service - instead, it requires a subscription. This is likely to deter young users, whose viral marketing has been one of the factors driving the service's Japanese success.

Published By Datamonitor
17 Apr 2002
CommentWire
CommentWire

GSK: antidepressant leader under threat

The Chicago court ruling will see Apotex's Paxil generic impact the GSK bi-blockbuster antidepressant from 2005. Moreover, GSK's follow up antidepressant, vilazadone, appears to be struggling to proceed to market, leaving GSK with a wealth of depression expertise but a foreseeable dent in its antidepressant revenue stream.

Published By Datamonitor
07 Mar 2003
CommentWire
CommentWire

GSK/Bayer: vardenafil closer to challenging Viagra

Pfizer's Viagra has monopolized the erectile dysfunction market, but will face competition from GSK/Bayer's vardenafil and Lilly's Cialis when these drugs launch in 2003. Whether the challengers will take substantial market share from Viagra, however, depends on whether GSK and Lilly can persuade physicians and consumers that they offer significant advantages.

Published By Datamonitor
26 Jul 2002
CommentWire
CommentWire

CryoCor: competing in cardiac cryoablation

Published By Datamonitor
17 Aug 2001
CommentWire
CommentWire

Boehringer Ingelheim: stroke drug may harm patients

The aptiganel results are just the latest in a string of disappointing results for neuroprotective agents in acute stroke. This casts serious doubt on this drug class' role in acute stroke, dashing early hopes that neuroprotective agents would fulfill a major unmet need in the anti-thrombosis market.

Published By Datamonitor
05 Dec 2001
CommentWire
CommentWire

Boehringer Ingelheim: Spiriva set for success

Published By Datamonitor
25 Sep 2001

« | 1 | 2 | » »|

No help is available.